Global Ovarian Cancer Research Consortium
Global Ovarian Cancer Research Consortium
The Global Ovarian Cancer Research Consortium unites four leading organizations across three continents to accelerate lifesaving progress through international research collaboration.
Global Ovarian Cancer Research Consortium
Global Ovarian Cancer Research Consortium
The Global Ovarian Cancer Research Consortium unites four leading organizations across three continents to accelerate lifesaving progress through international research collaboration.
About the Consortium
A Global Effort Sparked by Shared Urgency
The Consortium, formed in 2024, brings together leading ovarian cancer organizations — Ovarian Cancer Research Alliance in the United States, Ovarian Cancer Research Foundation (Australia), Ovarian Cancer Canada, and Ovarian Cancer Action (United Kingdom). Their mission: to combine forces, resources, and determination to accelerate progress where it’s desperately needed. Now in its second year, the Consortium is poised to rewrite the future of ovarian cancer care.
The AI Accelerator Grant
Artificial intelligence is transforming the field of cancer research—revolutionizing diagnosis, risk prediction, drug development, and personalized treatment. But ovarian cancer has yet to feel the full power of this transformation.
The Consortium’s Accelerator Grant aims to change that. These landmark $1 million grants, each paired with in-kind cloud compute support, fund international research teams harnessing the power of AI to improve survival outcomes. The Consortium launched its inaugural AI Accelerator Grant in 2025 with compute support from Microsoft’s AI for Good Lab. An international team of researchers received the first grant, harnessing AI to improve how survival and treatment response are predicted in high-grade serous ovarian cancer—the most common and deadly form of the disease. Building on that momentum, the Consortium has now announced a second $1 million AI Accelerator Grant, with compute support from Amazon Web Services (AWS).
This effort represents a bold step forward in ovarian cancer research and a model for future global initiatives.
Amazon Web Services (AWS)
Amazon Web Services is generously partnering on the second AI Accelerator Grant, donating in-kind cloud compute credits to the successful research team. AWS’s cloud computing power will enable selected applicants to conduct data-intensive, AI-driven research at the scale required to make meaningful progress against ovarian cancer.
Selected researchers will use AWS compute credits within OCRA’s Discovery Lab Trusted Research Environment (TRE), an AI-enabled, international, collaborative research platform — a shared ecosystem that enables real-time data analysis, cross-institutional collaboration, and the integration of diverse datasets from across the Consortium’s member organizations.
OCRA’s commitment to advancing ovarian cancer research through international collaboration represents hope. Hope that women worldwide will gain the access, resources, and breakthroughs needed to fight ovarian cancer. The global impact of this unified effort is profound.
The CEOs of the four founding organizations attended the 2024 Helene Harris Memorial Trust (HHMT) International Forum on Ovarian Cancer.
We formed the Consortium with one urgent goal: to supercharge breakthroughs in ovarian cancer research by working together in ways never done before. When we pool expertise, data, and determination across continents, we give scientists the tools—and the reach—they need to make transformative progress.
Founding Members
